CDSCO Medical Device Software Guidance 2026: Preparing For AI, Software-Based Medical Device Regulatory Compliance In India

How CDSCO Guidance on AI/ML, SaMD, SiMD, Risk Classification, Clinical Evidence, Cybersecurity, QMS, and Lifecycle Management Is Shaping India's Digital Health Regulatory Pathway

India's digital health sector is rapidly expanding through AI, machine learning, cloud platforms, mobile applications, connected devices, and clinical decision-support software. To provide greater regulatory clarity, CDSCO has issued guidance explaining how Medical Device Software (MDSW), including AI/ML-enabled products, will be regulated under the Medical Devices Rules, 2017 (MDR-2017).

The guidance applies to software that meets the medical-device definition under the Drugs and Cosmetics Act, 1940 and MDR-2017, including standalone, embedded, AI/ML, cloud, mobile, and IVD software. It does not apply to software intended only for general wellness, healthy lifestyle promotion, or routine fitness tracking.

Importantly, CDSCO states that the guidance clarifies existing MDR-2017 requirements rather than creating a new regulatory framework.

Why CDSCO Medical Device Software Guidance Is a Strategic Priority

Medical software increasingly supports:

• Diagnosis
• Screening
• Monitoring
• Prediction
• Treatment
• Clinical decision-making
• Medical device operation
• Digital healthcare delivery

Regulatory uncertainty can lead to:

• Incorrect classification
• Delayed approvals
• Incomplete technical documentation
• Insufficient clinical evidence
• Cybersecurity gaps
• Software validation issues
• Algorithm-change challenges
• PMS deficiencies
• Commercial delays

Regulatory readiness should therefore be integrated into the complete software lifecycle.

Executive Overview

A strong MDSW regulatory strategy should cover:

• CDSCO/MDR-2017 compliance
• Product qualification
• SaMD and SiMD assessment
• Intended-use definition
• Risk classification
• QMS
• Software design and validation
• AI/ML documentation
• Clinical evidence
• Cybersecurity
• Regulatory submission
• Licensing
• Version control
• Change management
• Post-market surveillance
• Regulatory intelligence

Understanding India's Medical Device Software Framework

Software intended for a medical purpose and meeting the medical-device definition is regulated as a medical device under MDR-2017.

Key Regulatory Authorities

What Is Medical Device Software?

Software as a Medical Device (SaMD)

Standalone software performing a medical function.

Examples:

• AI diagnostics
• Image analysis
• Clinical decision support
• Screening software
• Predictive healthcare tools

Software in a Medical Device (SiMD)

Software embedded in or controlling/influencing a medical device.

Examples:

• Embedded software
• Equipment control software
• Imaging software
• Device operating software

Software Outside the Regulatory Scope

Software may fall outside MDR-2017 where it is intended only for:

• General wellness
• Healthy lifestyle promotion
• Fitness tracking
• Routine body-parameter monitoring without a medical purpose

The intended purpose remains critical to determining regulatory status.

Intended Use: Foundation of the Regulatory Strategy

Manufacturers should clearly define:

• Medical purpose
• Disease/condition
• Patient population
• Intended users
• Use environment
• Input and outputs
• Clinical function
• Limitations
• Contraindications
• Deployment environment

For IVD software, this may also include:

• Analytes
• Specimens
• Testing methods
• Diagnostic outputs
• Testing limitations

Intended use influences classification, evidence, labeling, and licensing.

AI and Machine Learning Medical Devices

AI/ML products fall within the medical device framework when they meet the applicable medical-device definition.

Manufacturers should document:

• AI/ML architecture
• Training methodology
• Dataset sources
• Training/validation/testing datasets
• Dataset composition
• Demographics
• Geographic representation
• Performance
• Robustness
• Generalizability
• Bias assessment
• Model drift
• Cybersecurity
• Software changes

For AI products, particular attention should be given to population bias, Indian demographic representation, robustness, and generalizability.

Risk-Based Classification

Medical devices are classified into:

Classification depends on intended use and the applicable MDR-2017 rules. Software influencing hardware medical devices may also follow the applicable risk classification of the parent device.

Classification affects:

• Licensing authority
• Evidence requirements
• Technical documentation
• Regulatory review
• Testing
• Compliance obligations

Licensing and Regulatory Pathway

Relevant applications are handled through applicable digital regulatory systems, including NSWS and the MD Online Portal.

Clinical Evidence

Clinical evidence should demonstrate safety, performance, and effectiveness for the intended purpose.

Depending on the product, evidence may include:

• Clinical evaluation
• Clinical investigation
• Performance studies
• Validation data
• Safety information
• Effectiveness data
• Real-world evidence

For AI/ML products, performance should be evaluated across relevant populations and healthcare settings.

Quality Management System

MDSW manufacturers should establish a lifecycle-based QMS covering:

• Design and development
• Software requirements
• Risk management
• Verification and validation
• Configuration management
• Release management
• Maintenance
• Change control
• Documentation

Regulatory and quality controls should be integrated into software development rather than handled only before submission.

Software Verification and Validation

Manufacturers should demonstrate that:

• Software requirements are fulfilled
• Design outputs are controlled
• Software performs as intended
• Safety risks are addressed
• Versions are traceable
• Changes are tested and validated

AI systems should also be evaluated for model performance, dataset suitability, external validation, and relevant update/retraining risks.

Cybersecurity Compliance

Cybersecurity should cover the complete software lifecycle.

Organizations should address:

• Secure architecture
• Threat assessment
• Access controls
• Data integrity
• Confidentiality
• Availability
• Vulnerability management
• Security updates
• SBOM
• Incident response
• Secure deployment

Cloud, connected, interoperable, and network-enabled medical software require cybersecurity attention.

AI Risk Management

AI-specific risks may include:

• Algorithmic bias
• Limited explainability
• Model drift
• Poor generalizability
• Data-quality problems
• Incorrect outputs
• Demographic bias
• Cybersecurity vulnerabilities

These risks should be incorporated into formal risk-management processes.

Software Version and Algorithm Change Management

Software requires continuous lifecycle control.

Manufacturers should maintain:

• Version history
• Release dates
• Change descriptions
• Impact assessments
• Validation records
• Regulatory evaluations
• Change approvals

Where appropriate, an Algorithm Change Protocol (ACP) should be established to manage AI/ML modifications and retraining.

Major changes may require applicable approval, while other changes may require notification depending on the regulatory pathway.

Regulatory Submission Documentation

A typical submission may include:

• Administrative documents
• Intended use
• Device description
• Specifications
• Software architecture
• Software requirements
• Verification and validation
• Risk management
• Cybersecurity
• AI/ML information
• Dataset information
• Clinical evidence
• Performance data
• Labeling
• IFU
• QMS documentation
• Site/manufacturing information
• Applicable standards
• PMS information
• Version/release documentation

Labeling and Promotional Claims

Information should remain consistent across:

• Labels
• IFU
• Electronic instructions
• Software interface
• Website
• Marketing materials
• App stores
• Product documentation

Inconsistent medical claims can create regulatory risk, particularly when claims affect intended use.

Post-Approval Lifecycle Management

After commercialization, organizations must manage:

• Software updates
• Bug fixes
• Security pitches
• Algorithm changes
• Version releases
• Regulatory notifications
• Major/minor changes
• Risk reassessment
• PMS
• Corrective actions

Medical device software compliance is therefore an ongoing lifecycle activity.

Post-Market Surveillance

Manufacturers/importers should monitor:

• Adverse events
• Software malfunctions
• Performance degradation
• Cybersecurity vulnerabilities
• Algorithm drift
• Patient/user harm
• Complaints
• Corrective actions
• Real-world performance

Serious adverse events and relevant malfunctions must be handled according to applicable regulatory reporting requirements.

Real-World Evidence

Real-world evidence can strengthen understanding of software performance after commercialization.

Organizations should consider performance across:

• Patient populations
• Demographics
• Geographic settings
• Healthcare facilities
• Intended users
• Deployment environments

For AI products, Indian real-world data can be particularly important for assessing population relevance and model performance.

Regulatory Readiness Assessment

Best Practices

Organizations should:

• Define intended use early
• Assess SaMD/SiMD status
• Confirm classification before submission
• Establish a software QMS
• Integrate regulatory requirements into development
• Validate AI/ML systems using appropriate datasets
• Assess bias and generalizability
• Implement cybersecurity-by-design
• Maintain version control
• Establish ACP where applicable
• Plan clinical evidence early
• Align labeling and claims
• Build PMS before launch
• Monitor CDSCO updates continuously

Common Mistakes

Avoid:

• Assuming all healthcare apps are unregulated
• Treating medical AI as ordinary software
• Broad or unclear intended use
• Incorrect classification
• Weak clinical evidence
• Poor dataset characterization
• Ignoring population bias
• Weak cybersecurity
• Poor version control
• Uncontrolled algorithm changes
• Inconsistent promotional claims
• Late PMS planning
• Incomplete update documentation

Medical Device Software Regulatory Roadmap

Future Trends

Key developments include:

• AI-enabled medical devices
• Adaptive algorithms
• Real-world evidence
• Cybersecurity-by-design
• Software Bill of Materials
• Algorithm Change Protocols
• AI bias monitoring
• Model drift monitoring
• Cloud-based medical software
• Mobile medical applications
• Digital interoperability
• Stronger PMS
• Lifecycle-based regulation
• AI management systems

Relevant frameworks may include ISO/IEC 23894 for AI risk management and ISO/IEC 42001 for AI management systems.

Business Benefits

Frequently Asked Questions

1. What is the CDSCO Medical Device Software Guidance 2026?

It explains how software meeting the medical-device definition is regulated under MDR-2017.

2. Does it introduce a new regulatory framework?

No. It clarifies the application of the existing MDR-2017 framework.

3. Does it cover AI/ML?

Yes. AI/ML software can be regulated as MDSW when it meets the medical-device definition.

4. What is SaMD vs SiMD?

SaMD is standalone medical software; SiMD is software embedded in or influencing a medical device.

5. Are all healthcare apps regulated?

No. General wellness and fitness software without a medical purpose may fall outside MDR-2017.

6. How is software classified?

MDSW is classified as Class A, B, C, or D based on applicable risk rules and intended use.

7. Is clinical evidence required?

Requirements depend on the product, risk class, intended purpose, and regulatory pathway.

8. What AI information should be documented?

Architecture, datasets, training/validation methods, performance, bias, robustness, generalizability, and relevant changes.

9. Is cybersecurity important?

Yes. Cybersecurity should be addressed throughout the software lifecycle.

10. What happens when software changes?

Updates and changes must be assessed and managed under the applicable post-approval change requirements.

11. Is PMS required?

Yes. Manufacturers/importers should maintain ongoing post-market surveillance.

12. How can Maven Regulatory Solutions help?

Maven supports:

• CDSCO regulatory strategy
• MDSW qualification
• SaMD/SiMD assessment
• Risk classification
• MDR-2017 compliance
• AI/ML regulatory strategy
• Technical documentation
• Clinical evidence planning
• QMS readiness
• Cybersecurity compliance
• Regulatory submissions
• Labeling compliance
• Change management
• PMS and vigilance
• Regulatory intelligence
• Global medical device consulting

Conclusion

CDSCO's 2026 Medical Device Software guidance provides important clarity for India's rapidly growing AI and digital health sector. By connecting intended use, risk classification, QMS, clinical evidence, AI governance, cybersecurity, software validation, licensing, change management, and PMS, the guidance establishes a more structured lifecycle-based approach to medical software compliance.

Companies developing AI diagnostics, clinical decision-support tools, imaging platforms, connected devices, and digital medical applications should build regulatory controls into product development from the beginning.

Why Choose Maven Regulatory Solutions?

Maven Regulatory Solutions provides end-to-end support for organizations navigating India's medical device and digital health regulations.

Our expertise includes CDSCO strategy, MDR-2017 compliance, MDSW qualification, SaMD/SiMD classification, AI/ML regulatory strategy, technical documentation, clinical evidence, QMS, cybersecurity, submissions, post-approval change management, PMS, vigilance, and regulatory intelligence.

We help organizations convert complex regulatory requirements into practical compliance strategies for confident product development and market entry.